**EQUITY RESEARCH - COMPANY REPORT** 



## **MASTER STYLE**

**MASTER TB** 

THAILAND / SERVICES

# **Profit sharing is coming**

- We expect 2Q24 net profit to grow q-q and y-y, due to the recovery of Masterpiece Hospital's revenue and higher profit sharing.
- MASTER will begin recognizing V Square's contribution in June and will fully recognize it from 3Q24 onward.
- The Skin Clinic and Dr. Chen hospital should support in 2H24.

## New Dr. Chen hospital aims to break even in 4Q24

Dr. Chen hospital, in which MASTER has a 40% stake, is located in Soi Ramkhamhaeng 106. The hospital has a total of six operating rooms and is currently running two operating rooms. MASTER recognized a share of loss of THB75,000 in 1Q24 and is in the process of marketing to expand its customer base, using agencies to attract international customers from places like Hong Kong and China. In addition, Dr. Chen hospital also uses doctors from MASTER to provide a variety of plastic surgery services, leveraging their expertise in facial surgery. Dr. Chen plans to open all six operating rooms in 2H24 and aims to break even in 4Q24.

## Recognizing profit sharing from V Square in June 2024

Regarding V Square (MASTER has a 40% stake), there are currently 27 branches in total, with three new branches opened in 1H24 (Central Plaza Nakhon Pathom, Praram 9, and Mega Bangna) and five more to open in 2H24, for a total of eight new branches in 2024. Its key feature is dermatologists who specialize in injections, and the clinic is expanding its services to include more equipment, e.g. for hair removal. Its main marketing strategy is word of mouth. MASTER will begin recognizing V Square's contribution in June and fully recognize it from 3Q24 onward.

## The Skin Clinic should support MASTER from 3Q24 onward

The Skin Clinic (MASTER owns 40%), a hair treatment specialist, has seven branches and serves through one hospital. It is one of the top five hair treatment companies in Thailand. Management plans to renovate the first hair treatment hospital in Rama 3 in 3Q24, with an estimated opening in mid-2025. The Skin Clinic also plans to expand its hair loss and thinning treatment services by introducing high-tech equipment to other clinics in the Master Group. MASTER plans to recognize a share of profit from The Skin Clinic from 3Q24 onward.

## Expect 2Q24 profit to grow q-q and y-y, and accelerate in 2H24

We anticipate MASTER's 2Q24 net profit to be THB127m (+20% q-q, +56% y-y), due to the recovery of Masterpiece Hospital's revenue on a q-q basis. MASTER also expects to recognize profit sharing from seven associates in 2Q24, up from six in 1Q24, with the profit contribution expected to increase to THB15m from THB10m in 1Q24, and accelerate in 2H24. MASTER plans to recognize a higher profit contribution in 2H24, increasing to nine and 13 companies in 3Q24 and 4Q24, respectively.

## BUY

**UNCHANGED** 

TARGET PRICE THB72.00
CLOSE THB64.50
UP/DOWNSIDE +11.6%
PRIOR TP THB72.00
CHANGE IN TP UNCHANGED
TP vs CONSENSUS -4.4%

### **KEY STOCK DATA**

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	1,917	2,326	2,556	2,861
Net profit	416	621	685	763
EPS (THB)	1.58	2.06	2.27	2.53
vs Consensus (%)	-	0.1	(3.8)	(11.6)
EBITDA	586	719	800	902
Recurring net profit	416	621	685	763
Core EPS (THB)	1.58	2.06	2.27	2.53
Chg. In EPS est. (%)	-	nm	nm	nm
EPS growth (%)	(2.2)	30.6	10.3	11.3
Core P/E (x)	40.9	31.3	28.4	25.5
Dividend yield (%)	0.4	1.0	1.4	1.6
EV/EBITDA (x)	28.5	27.0	24.0	20.9
Price/book (x)	5.7	5.6	5.0	4.5
Net debt/Equity (%)	(11.1)	(1.2)	(6.6)	(13.3)
ROE (%)	24.5	19.3	18.7	18.6



Share price performance	1 Month	3 Month	12 Month	
Absolute (%)	4.5	(7.2)	(3.2)	
Relative to country (%)	8.0	(3.4)	10.5	
Mkt cap (USD m)			531	
3m avg. daily turnover (USD m)			2.8	
Free float (%)			0	
Major shareholder	Masc	hamadol fa	mily (68%)	
12m high/low (THB)		7	4.00/36.31	
sued shares (m) 301				

Sources: Bloomberg consensus; FSSIA estimates



**Sureeporn Teewasuwet** Fundamental Investment Analyst on Securities; License no. 040694 sureeporn.t@fssia.com, +66 2646 9972

#### Investment thesis

We expect Thailand's cosmetic surgery market to grow by 9.7% CAGR in 2023-30, close to global cosmetic surgery markets. Additionally, the medical tourism trend should support surgery hospitals in Thailand to have a higher revenue mix from international customers, which would in turn support future growth.

MASTER has several strengths. It has earned a good reputation and has become well-known over the past ten years. Given the experience of Dr. Raweewat Maschamadol and other renowned doctors, MASTER has gained customer trust, leading to referrals and positive reviews on social media. It has also expanded and invested in other businesses to further its long-term growth.


## Company profile

MASTER is in the cosmetic surgery hospital business under Masterpiece Hospital. Established in 2012, it has 17 operating beds and offers one-stop cosmetic surgery services. MASTER earns revenue from four services, including surgery, skin, hair treatment, and aftercare, with surgery contributing the highest revenue of 81% of total revenue.

www.masterpiecehospital.com

## Principal activities (revenue, 2023)

- Surgery 81.0 %
- Skin 7.1 %
- Hair treatment 6.0 %
- Aftercare 3.6 %
- Others 2.3 %




Source: Master Style

## **Major shareholders**

■ Maschamadol family - 68.0 %

■ Others - 32.0 %



Source: Master Style

## **Catalysts**

2024 potential growth drivers include 1) more surgery customers; 2) a higher utilization rate for operating beds, which would drive operating leverage; and 3) the realization of profit and synergies from M&As.

#### Risks to our call

Downside risks to our P/E-based TP include 1) increased competition; 2) a pandemic that results in a lockdown; 3) lower-than-expected utilization rate of new operating beds; 4) higher-than-expected doctor costs and expenses; and 5) a loss contribution from the acquired units.

## **Event calendar**

Date	Event
August 2024	2Q24 results announcement

## **Key assumptions**

	2024E	2025E	2026E
Total OR rooms (no.)	17	17	17
Capacity hours (hours)	80,665	80,665	80,665
Operating hours (hours)	58,079	60,499	64,532
Utilization rate (%)	72.0	75.0	80.0


Source: FSSIA estimates

### **Earnings sensitivity**

- For every 5% increase in revenue, we estimate 2024 net profit to rise by 3.9%, and vice versa, all else being equal.
- For every 0.5% increase in GPM, we estimate 2024 net profit to rise by 2%, and vice versa, all else being equal.
- For every 1% increase in SG&A, we estimate 2024 net profit to fall by 3.5%, and vice versa, all else being equal.

Source: FSSIA estimates

Exhibit 1: Timeline to recognize profit sharing from associate companies



Source: MASTER

Exhibit 2: Services and information about V Square




Source: MASTER

Exhibit 3: MASTER – 2Q24E earnings preview

	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24E	Chai	nge	1H23	1H24E	Change
	(THB m)	(q-q%)	(y-y%)	(THB m)	(THB m)	(y-y%)					
Sales	436	459	479	543	468	501	7.0	9.1	895	969	8.3
Cost of sales	182	204	200	198	194	205	5.8	0.4	387	400	3.3
Gross profit	253	255	279	345	274	295	7.9	16.0	508	569	12.0
SG&A	162	158	160	154	160	163	1.8	3.7	320	324	1.2
Operating profit	94	106	128	197	122	142	16.1	34.4	199	265	32.7
Profit sharing	0	0	0	5	10	15	49.2	nm	0	25	nm
Interest expense	3	4	4	3	3	3	0.5	(2.9)	7	7	(3.0)
Tax expense	19	21	25	40	23	28	18.6	33.6	39	51	30.2
Reported net profit	72	81	100	164	106	127	19.5	55.8	153	233	52.4
Core profit	72	81	100	164	106	127	19.5	55.8	153	233	52.4
Key Ratios (%)							(ppt)	(ppt)			
Gross margin	58.2	55.5	58.2	63.6	58.5	59.0	0.5	3.5	56.8	58.8	2.0
SG&A to sales	37.2	34.3	33.5	28.3	34.3	32.6	(1.7)	(1.7)	35.7	33.4	(2.3)
Operating margin	21.5	23.1	26.8	36.3	26.2	28.4	2.2	5.3	22.3	27.3	5.0
Net margin	16.4	17.7	20.8	30.1	22.7	25.3	2.7	7.6	17.1	24.1	7.0
Core margin	16.4	17.7	20.8	30.1	22.7	25.3	2.7	7.6	17.1	24.1	7.0


Sources: MASTER, FSSIA estimates

**Exhibit 4: Total revenue** 




 $Sources: MASTER, FSSIA\ estimates$ 

Exhibit 6: Gross margin and SG&A to sales




Sources: MASTER, FSSIA estimates

Exhibit 5: Operating hours and utilization rate



Sources: MASTER, FSSIA estimates

Exhibit 7: Net profit and growth



Sources: MASTER, FSSIA estimates

## **Financial Statements**

Master Style

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	1,483	1,917	2,326	2,556	2,861
Cost of goods sold	(641)	(785)	(949)	(1,038)	(1,159)
Gross profit	841	1,132	1,377	1,518	1,702
Other operating income	8	27	33	33	37
Operating costs	(463)	(634)	(768)	(844)	(944)
Operating EBITDA	422	586	719	800	902
Depreciation	(35)	(62)	(77)	(92)	(107)
Goodwill amortisation	0	0	0	0	0
Operating EBIT	386	525	642	708	795
Net financing costs	(4)	(9)	(9)	(9)	(9)
Associates	0	5	125	137	144
Recurring non-operating income	0	5	125	137	144
Non-recurring items	0	0	0	0	0
Profit before tax	383	521	758	836	930
Tax	(76)	(105)	(136)	(150)	(167)
Profit after tax	306	416	621	685	763
Minority interests	-	-	-	-	-
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	306	416	621	685	763
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	306	416	621	685	763
Per share (THB)					
Recurring EPS *	1.61	1.58	2.06	2.27	2.53
Reported EPS	1.61	1.58	2.06	2.27	2.53
DPS	0.30	0.27	0.62	0.91	1.01
Diluted shares (used to calculate per share data)	190	264	302	302	302
Growth					
Revenue (%)	124.8	29.3	21.4	9.9	11.9
Operating EBITDA (%)	73.9	39.1	22.5	11.3	12.8
Operating EBIT (%)	82.7	35.9	22.3	10.3	12.3
Recurring EPS (%)	0.0	(2.2)	30.6	10.3	11.3
Reported EPS (%)	0.0	(2.2)	30.6	10.3	11.3
Operating performance					
Gross margin inc. depreciation (%)	56.7	59.1	59.2	59.4	59.5
Gross margin exc. depreciation (%)	59.1	62.3	62.5	63.0	63.2
Operating EBITDA margin (%)	28.4	30.6	30.9	31.3	31.5
Operating EBIT margin (%)	26.1	27.4	27.6	27.7	27.8
Net margin (%)	20.7	21.7	26.7	26.8	26.7
Effective tax rate (%)	19.9	20.1	18.0	18.0	18.0
Dividend payout on recurring profit (%)	18.6	17.0	30.0	40.0	40.0
Interest cover (X)	102.2	62.2	81.7	90.8	101.7
Inventory days	26.8	41.1	42.8	42.0	41.8
Debtor days	0.9	1.1	1.1	1.0	0.9
Creditor days	34.7	64.9	62.6	47.2	47.0
Operating ROIC (%)	115.1	37.7	33.0	43.0	46.8
ROIC (%)	82.1	25.8	20.2	19.2	20.4
ROE (%)	107.4	24.5	19.3	18.7	18.6
ROA (%)  * Pre-exceptional, pre-goodwill and fully diluted	40.0	18.5	16.3	16.1	16.2
	2022	2023	2024E	2025E	2026E
Revenue by Division (THB m)					
Surgery	1,194	1,553	1,908	2,087	2,337
Skin	106	136	161	185	210
Hair treatment	90	115	136	154	175
Aftercare	62	70	75	82	88

Sources: Master Style; FSSIA estimates

## **Financial Statements**

Master Style

Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	306	416	621	685	763
Depreciation	35	62	77	92	107
associates & minorities	0	0	0	0	(
Other non-cash items	0	(5)	(125)	(137)	(144)
Change in working capital	(100) <b>242</b>	74 <b>547</b>	(38) <b>534</b>	18 <b>658</b>	735
ash flow from operations apex - maintenance	242	547	534	000	/35
Capex - new investment	(413)	(2,179)	(673)	(171)	(107
Net acquisitions & disposals	-	-	-	-	(
Other investments (net)	-	-	-	-	
Cash flow from investing	(413)	(2,179)	(673)	(171)	(107)
Dividends paid	(263)	(99)	(189)	(274)	(305)
Equity finance	198	2,270	38	0	(
Debt finance	159	(11)	(2)	(2)	(2)
Other financing cash flows	(1)	2	0	0	(200
Cash flow from financing Non-recurring cash flows	93	2,161	(153)	(275)	(306)
Other adjustments	0	0	0	0	
let other adjustments	(5)	0	ŏ	0	Č
Novement in cash	(83)	529	(292)	212	321
ree cash flow to firm (FCFF)	(162.06)	(1,618.40)	(124.27)	501.30	641.76
ree cash flow to equity (FCFE)	(18.91)	(1,641.98)	(140.56)	485.65	626.33
Per share (THB)					
CFF per share	(0.54)	(5.36)	(0.41)	1.66	2.13
FCFE per share	(0.06)	(5.44)	(0.47)	1.61	2.08
Recurring cash flow per share	1.80	1.79	1.90	2.12	2.40
Balance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
angible fixed assets (gross)	498	1,242	1,578	1,665	1,740
.ess: Accumulated depreciation	(73)	(339)	(366)	(395)	(427)
Tangible fixed assets (net)	424	903	1,211	1,270	1,313
ntangible fixed assets (net)	7	7	7	7	
ong-term financial assets	8	15	15	15	1:
nvest. in associates & subsidiaries Cash & equivalents	0 98	362 627	1,861 335	2,019 547	2,060 86
A/C receivable	5	7	6	7	8
nventories	63	101	104	, 114	127
Other current assets	166	1,136	302	281	315
Current assets	331	1,871	748	949	1,31
Other assets	177	480	233	256	28
Total assets	947	3,637	4,074	4,515	4,998
Common equity	404	2,991	3,461	3,872	4,330
Minorities etc.	0	0	0	0	
Total shareholders' equity	404	2,991	3,461	3,872	4,33
ong term debt	291 3	294 5	292	291	28
Other long-term liabilities .ong-term liabilities	294	298	5 <b>297</b>	2 <b>96</b>	29:
A/C payable	148	260	210	230	25
Short term debt	15	2	2	2	20
Other current liabilities	86	86	105	115	114
Current liabilities	249	348	316	347	37
Total liabilities and shareholders' equity	947	3,637	4,074	4,515	4,99
Net working capital	0	898	98	57	7
nvested capital Includes convertibles and preferred stock which is bei	616	2,664	3,424	3,623	3,75
·	ng treated as debt				
Per share (THB)  Book value per share	2.12	11 22	11 /7	12.92	14.9
оок value per snare angible book value per share	2.12	11.33 11.30	11.47 11.45	12.83 12.81	14.3 14.3
Financial strength	2.03	11.50	11.40	12.01	14.3
let debt/equity (%)	51.7	(11.1)	(1.2)	(6.6)	(13.3
Net debt/total assets (%)	22.1	(9.1)	(1.0)	(5.6)	(11.6
Current ratio (x)	1.3	5.4	2.4	2.7	3.
CF interest cover (x)	105.2	64.0	57.8	71.6	80.
'aluation	2022	2023	2024E	2025E	2026
ecurring P/E (x) *	40.0	40.9	31.3	28.4	25.
Recurring P/E @ target price (x) *	44.7	45.7	35.0	31.7	28.
Reported P/E (x)	40.0	40.9	31.3	28.4	25.
Dividend yield (%)	0.5	0.4	1.0	1.4	1.
Price/book (x)	30.4	5.7	5.6	5.0	4.
Price/tangible book (x)	30.9	5.7	5.6	5.0	4.
EV/EBITDA (x) **	29.6	28.5	27.0	24.0	20.
EV/EBITDA @ target price (x) **	32.9	31.9	30.2 5.7	26.8 5.3	23. 5.
EV/invested capital (x)	20.2	6.3			

Sources: Master Style; FSSIA estimates

## **Disclaimer for ESG scoring**

ESG score	Methodolog	у			Rating					
The Dow Jones Sustainability Indices ( <u>DJSI</u> ) By S&P Global	process bas from the ann	ed on the comp nual S&P Globa	ransparent, rules-based oanies' Total Sustainabili al Corporate Sustainabilit unies within each industry	ity Scores resulting ty Assessment (CSA).	Sustainability Assessment (CSA) for DJSI. Companies with an S&P G					
Sustainability nvestment List (THSI) by The Stock Exchange of Thailand (SET)	managing b Candidates 1) no irregul float of >150 up capital. S 70%; 2) inde wrongdoing	usiness with tra must pass the ar trading of the shareholders, some key disque ependent direct related to CG,	ity in Environmental and ansparency in Governand preemptive criteria, with e board members and en and combined holding or alifying criteria include: 1 ors and free float violatic social & environmental in arnings in red for > 3 yea	ce, updated annually. two crucial conditions: tecutives; and 2) free nust be >15% of paid- 1) CG score of below on; 3) executives' mpacts; 4) equity in	during the assessment year. The scoring will be fairly weighted according to the relevant industry and materiality.  SETTHSI Index is extended from the THSI companies whose 1) in acapitalization > THB5b (~USD150b); 2) free float >20%; and 3) lice >0.5% of paid-up capital for at least 9 out of 12 months. The SET Index is a market capitalisation-weighted index, cap 5% quarterly					
CG Score by Thai nstitute of Directors Association Thai IOD)	annually by Thailand (SI	the Thai IOD, v	n in sustainable developn with support from the Sto s are from the perspectiv i.	ck Exchange of	Good (80-89), and not rated for equitable treater	3 for Good (70 or scores belo ment of shareh 25%); 4) disclo	ories: 5 for Excel 0-79), 2 for Fair (6 w 50. Weightings nolders (weight 2 sure & transpare	60-69), 1 for P include: 1) th 5% combined	lass (60-69), ne rights; 2) an ); 3) the role o	
AGM level By Thai nvestors Association (TIA) with support from the SEC	treatment ar transparent out of five th criteria cove date (45%), circulation of s exercised. The and verifiability	re incorporated and sufficiently and sufficiently are CG component AGM proceduland after the most after information assesses by; and 3) opennesses.	hich shareholders' rights into business operations disclosed. All form impo ents to be evaluated annures before the meeting (10%). (The first as ion for voting; and 2) facilitating the ease of attending mess for Q&A. The third involves, resolutions and voting res	a and information is intant elements of two ually. The assessment (45%), at the meeting assesses 1) advance ing how voting rights can be eetings; 2) transparency is the meeting minutes that			four categories: (80-89), and not			
Fhai CAC By Thai Private Sector Collective Action Against Corruption CAC)	establishme policies. The (Companies of Declaration of Certification, in managers and	nt of key control  Certification is  Ceciding to become  Intent to kick off a  nocluding risk asse	ols, and the monitoring all s good for three years. e a CAC certified member st. an 18-month deadline to sub- issment, in place of policy and blishment of whistleblowing	rified member start by submitting a professionalism and ethical achievements. blace of policy and control, training of fwhistleblowing channels, and					CAC Council	
Morningstar Sustainalytics	based on ar risk is unma	n assessment o naged. <i>Sources</i>	sk rating provides an ove f how much of a compan to be reviewed include corpo er media, NGO reports/webs	ny's exposure to ESG prate publications and			score is the sum higher ESG risk		ed risk. The	
	information, co		, ESG controversies, issuer t		<b>NEGL</b> 0-10	<b>Low</b> 10-20	Medium 20-30	<b>High</b> 30-40	Severe 40+	
ESG Book	positioned to the principle helps explai over-weighti	o outperform ov of financial ma n future risk-ad	ustainable companies the ver the long term. The me ateriality including informa justed performance. Mat h higher materiality and in the basis.	ethodology considers ation that significantly eriality is applied by	scores using m	ateriality-base	ated as a weight d weights. The s dicating better p	core is scaled		
MSCI			neasure a company's ma						nethodology to	
	AAA	8.571-10.000								
	AA	7.143-8.570	Leader:	leading its industry in m	anaying trie most s	igilliodiil ESG fl	ono anu opportunitie	70		
	Α	5.714-7.142		a material de	-14			des en l	- tat	
	BBB	4.286-5.713	Average:	a mixed or unexceptional industry peers	ai track record of m	anaging the mos	st significant ESG ris	sks and opportu	nities relative to	
	ВВ	2.857-4.285		, .						
	В	1.429-2.856	Laggard:	lagging its industry base	ed on its high expos	ure and failure t	o manage significar	it ESG risks		
	ccc	0.000-1.428	334141			a .a.iai o t	go o.griinodi			
loody's ESG olutions	believes tha	t a company in	ree to which companies t tegrating ESG factors int r shareholders over the r	o its business model and						
Refinitiv ESG rating	based on pu	ıblicly available	and objectively measure and auditable data. The a publicly. (Score ratings a	score ranges from 0 to	100 on relative E	SG performar	nce and insufficie	nt degree of t		
S&P Global			e is a relative score mea n the same industry clas				of ESG risks, op	portunities, ar	nd impacts	
Bloomberg	ESG Score		score is based on Bloom	ating the company's agg nberg's view of ESG fina the weights are determin	ıncial materiality.	The score is	a weighted gene	ralized mean (	(power mean)	

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

### **GENERAL DISCLAIMER**

## ANALYST(S) CERTIFICATION

### Sureeporn Teewasuwet FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

## History of change in investment rating and/or target price



Date Rating Target price Date Rating Target price Date Rating Target price Date Rating Target price

12-Dec-2023 BUY 71.00 27-Feb-2024 BUY 82.00 19-Mar-2024 BUY 72.00

Sureeporn Teewasuwet started covering this stock from 12-Dec-2023

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Master Style	MASTER TB	THB 64.50	BUY	Downside risks to our P/E-based TP include 1) increased competition; 2) a pandemic that results in a lockdown; 3) lower-than-expected utilization rate of new operating beds; 4) higher-than-expected doctor costs and expenses; and 5) a loss contribution from the acquired units.

Source: FSSIA estimates

#### **Additional Disclosures**

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 25-Jun-2024 unless otherwise stated.

### RECOMMENDATION STRUCTURE

## Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price\* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

\* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

### **Industry Recommendations**

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

#### **Country (Strategy) Recommendations**

**Overweight (O).** Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Neutral (N).** Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Underweight (U).** Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.